Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina

Overview

Atherosclerotic cardiovascular disease is a leading cause of mortality in our countries. Clinically, symptoms could be chest pain suggesting stable angina. Atherosclerosis is influenced by cardiovascular risk factors which obesity (Body Mass Index>30). Obesity is associated with an increase risk of cardiovascular complications. Lipoprotein(a) is regarded as an independent risk factor for premature cardiovascular disease. Lp(a) is composed of low-density lipoprotein – like particle bound to glycoprotein molecule: apolipoprotein(a). Plasma levels are determinated to more than 90% by genetic factors (no significant influence of statin, weight, lifestyle factor: diet, exercise). Two study with few patients have found that aspirin lowers serum Lp(a) levels. Elevated Lp(a) is a risk factor for recurrent coronary events in obese patient. Atherosclerosis is associated with imbalance of coagulation. TFPI (tissue factor pathway inhibitor) is the earliest inhibitor of the blood coagulation process, natural direct inhibitor of tissue factor. In-vitro, TFPI activity is inhibited by high Lp(a) . The aim of this study is to research reverse association between Lp(a) and TFPI activity in obese patient with chest pain like stable angina suggesting atherosclerotic heart disease and effect of aspirin.

Full Title of Study: “Search a Correlation Between Lipoprotein(a) Rate and TFPI(Tissue Factor Pathway Inhibitor)Activity in Obese Patients With Chest Pain Like Angina”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: February 2014

Interventions

  • Other: blood sample
    • blood sample at inclusion and 1 month after inclusion

Arms, Groups and Cohorts

  • obese men
    • obese men with chest pain like angina

Clinical Trial Outcome Measures

Primary Measures

  • correlation between Lp(a) and TFPI activity
    • Time Frame: day 1
    • Establish correlation between Lp(a) rate and TFPI activity in obese patients with chest pain like stable angina

Secondary Measures

  • Correlation between Lp(a) and TFPI resistance
    • Time Frame: day 1
    • Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment
  • Correlation between lp(a) rate and TFPI activity
    • Time Frame: 1 month
    • Establish the correlation, 1 month after initiation of aspirin treatment, between lp(a) rate and TFPI activity
  • thrombin generation
    • Time Frame: day 1
    • describe thrombin generation with calibrated automated thrombinography technique in obese patient with chest pain like angina and hight Lp(a)rate
  • Correlation between Lp(a) and TFPI resistance
    • Time Frame: 1 month
    • Establish correlation between Lp(a) rate and TFPI resistance at inclusion and 1 month after aspirin treatment

Participating in This Clinical Trial

Inclusion Criteria

  • Major – Men – Obese BMI>30 – No aspirin treatment before inclusion – Coronary exploration: coronary angiography or tomography coronary angiography – Chest pain like stable angina Exclusion Criteria:
  • Women – Severe hepatic insufficiency – Inflammatory disease – Neoplasia – Protein S deficiency – Aspirin treatment 10 days before inclusion – Oral anticoagulant treatment at inclusion – Heparin or low molecular weight heparin treatment at inclusion
  • Gender Eligibility: Male

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Centre Hospitalier Universitaire de Saint Etienne
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Brigitte TARDY, MD, Principal Investigator, CHU de Saint-Etienne

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.